Nevigramonum

Nevigramonum – уроантисептик groups of hinolon with the expressed antibacterial action on gram-negative bacteria.

Form of release and structure

Dosage form – capsules: gelatinous, the size No. 0, firm opaque structure, with the case and a lid of yellow color, in capsules – powder from white with a yellow shade till white color (on 56 pieces in polystyrene bottles, in a cardboard pack 1 bottle).

Active ingredient of Nevigramonum – Acidum nalidixicum, in 1 capsule – 0,5 g.

Auxiliary components: stearic acid, silicon dioxide colloid.

Structure of a cover of the capsule: titanium dioxide (E171), dye quinolinic yellow (E104), gelatin, dye sunset yellow (E110).

Indications to use

Use of Nevigramonum is shown for treatment of the infectious diseases caused by microorganisms, susceptible to drug:

• Cholecystitis;
• Infections of the digestive tract (DT);
• Cystitis;
• Pyelonephritis;
• Urethritis;
• Prostatitis.

Besides, capsules are appointed for prevention of infections at an operative measure on ureters, kidneys, a bladder.

Contraindications

• Parkinson's disease;
• Epilepsy;
• Severe form of atherosclerosis of vessels of a brain;
• Liver failure;
• Porphyria;
• Deficit glyukozo-6-fosfatdegidrogenazy;
• Renal failure;
• I trimester of pregnancy;
• Age up to 12 years;
• Feeding period breast;
• Individual intolerance of components of drug.

With care patients are recommended to appoint Nevigramonum aged from 12 up to 18 years.

To women in the II-III trimesters of pregnancy (especially last month of incubation) drug can be appointed provided that the advantage for mother exceeds potential risk for a fruit as safety of use of Nevigramonum during pregnancy is not established.

Route of administration and dosage

Capsules of Nevigramonum should be accepted inside in 1 hour prior to food.

The recommended dosing:

• Adults: on 2 capsules 4 times a day, duration of treatment is not less than 7 days. In need of extension of the period of therapy, the single dose should be lowered to 1 capsule. For patients of advanced age dose adjustment is not required;
• Children are more senior than 12 years (at body weight more than 40 kg): from calculation for 50 mg on 1 kg of body weight a day, the dose is divided into 3-4 receptions in equal shares.

Side effects

• Nervous system: weakness, drowsiness, dizziness, headache; seldom – toxic psychosis, increase in intracranial pressure, a spasm (at patients with epilepsy, cerebral arteriosclerosis); in some cases – paralysis of the sixth cranial nerve (passing);
• Digestive tract: nausea, pains in epigastriums, vomiting, diarrhea;
• Visual system: decrease in visual acuity, a diplopia, focusing difficulty, disturbance of color perception (at cancellation or a dose decline of drug usually pass);
• Dermatological reactions: a photosensitivity (erubescence, emergence of the bubbles which are completely passing after drug withdrawal within 2-8 weeks);
• Allergic reactions: itch, rash, urticaria, eosinophilia, swelling of joints, arthralgia; seldom – anaphylactoid reactions, a Quincke's disease, an acute anaphylaxis;
• Others: seldom – paresthesia, a metabolic acidosis, a cholestasia, thrombocytopenia, a leukopenia, hemolitic anemia with the advent of deficit glyukozo-6-fosfatdegidrogenazy.

Special instructions

It is recommended to approach with extra care purpose of Nevigramonum to patients more young than 18 years as there is a big risk of development of an arthralgia and an erosion of cartilaginous tissue of joints. At emergence of symptoms of the specified pathologies use of drug should be cancelled immediately.

During treatment influence of direct sunshine is contraindicated to the patient, at emergence of a photosensitivity therapy by Acidum nalidixicum is stopped.

In case of manifestation of symptoms of psychosis, increase in intracranial pressure, manifestation of signs of toxic effect of drug its reception needs to be cancelled.

Development of bacterial resistance to Acidum nalidixicum usually happens within 48 hours after the beginning of reception. Emergence of cross resistance at simultaneous use of drug with Acidum oxolinicum and tsinoksatsiny is possible.

For the analysis of urine at the patients accepting Nevigramonum it is necessary to use glyukozo-oksidazny methods of a research.

During administration of drug the patient is recommended to be careful at control of vehicles and mechanisms.

Medicinal interaction

At simultaneous use of Nevigramonum:

• Warfarin, bis hydroxycoumarin (peroral forms) can strengthen the action therefore dose adjustment of anticoagulants is required;
• Melphalanum increases risk of development of gastrointestinal toxicity;
• Probenetsid, suppressing secretion of Acidum nalidixicum in renal tubules, reduces its action at treatment of infectious pathologies of urinogenital system, at the same time increasing probability of emergence of system side effects.

Nitrofurantoin (the antagonist of Acidum nalidixicum) and other antibacterial connections (chloramphenicol, tetracycline) at a combination to drug suppress its action.

Terms and storage conditions

To protect from children.

To store in the place protected from light at a temperature up to 25 °C.

Period of validity – 5 years.